ZA200406765B - Anti-CCR5 antibody - Google Patents

Anti-CCR5 antibody

Info

Publication number
ZA200406765B
ZA200406765B ZA200406765A ZA200406765A ZA200406765B ZA 200406765 B ZA200406765 B ZA 200406765B ZA 200406765 A ZA200406765 A ZA 200406765A ZA 200406765 A ZA200406765 A ZA 200406765A ZA 200406765 B ZA200406765 B ZA 200406765B
Authority
ZA
South Africa
Prior art keywords
atcc deposit
deposit designation
plasmid designated
designation pta
ccr5
Prior art date
Application number
ZA200406765A
Other languages
English (en)
Inventor
William C Olson
Paul J Maddon
Naoya Tsurushita
Paul R Hinton
Maximillano Vasquez
Original Assignee
Progenics Pharm Inc
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc, Protein Design Labs Inc filed Critical Progenics Pharm Inc
Publication of ZA200406765B publication Critical patent/ZA200406765B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
ZA200406765A 2002-02-22 2004-08-25 Anti-CCR5 antibody ZA200406765B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8112802A 2002-02-22 2002-02-22

Publications (1)

Publication Number Publication Date
ZA200406765B true ZA200406765B (en) 2006-06-28

Family

ID=27765254

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200406765A ZA200406765B (en) 2002-02-22 2004-08-25 Anti-CCR5 antibody

Country Status (20)

Country Link
EP (2) EP2058006A1 (es)
JP (1) JP2006508631A (es)
KR (1) KR20050004784A (es)
CN (1) CN1780907B (es)
AT (1) ATE414142T1 (es)
AU (1) AU2003217674C1 (es)
CA (1) CA2476901C (es)
CY (1) CY1108799T1 (es)
DE (1) DE60324664D1 (es)
DK (1) DK1478738T3 (es)
ES (1) ES2316740T3 (es)
HK (1) HK1072272A1 (es)
IL (1) IL163655A0 (es)
MX (1) MXPA04008153A (es)
NO (1) NO20043971L (es)
NZ (2) NZ534947A (es)
PT (1) PT1478738E (es)
RU (1) RU2322454C2 (es)
WO (1) WO2003072766A1 (es)
ZA (1) ZA200406765B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858298B1 (en) 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
MX2008000984A (es) * 2005-07-22 2008-04-04 Progenics Pharm Inc Metodos para reducir la carga viral en pacientes infectados con vih-1.
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
JP2010500984A (ja) 2006-08-17 2010-01-14 エフ．ホフマン−ラ ロシュ アーゲー Ｃｃｒ５に対する抗体と抗膜融合ペプチドとの抱合体
KR20090052358A (ko) 2006-09-29 2009-05-25 에프. 호프만-라 로슈 아게 Ｃｃｒ5 에 대한 항체 및 이의 용도
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
EP2331133A4 (en) * 2008-09-05 2012-09-12 Univ Duke ANTILIPID ANTIBODIES
WO2011109365A2 (en) * 2010-03-01 2011-09-09 Progenics Pharmaceuticals, Inc. Concentrated protein formulations and uses thereof
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
CA2988650A1 (en) 2015-06-23 2016-12-29 Cytodyn Inc. Inhibition of ccl5 ligand binding to ccr5 receptor and alteration of ccr5/ccl5 axis signaling in inflammation, cancer, autoimmune, and other conditions
WO2017087547A1 (en) * 2015-11-17 2017-05-26 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
KR20220127859A (ko) * 2020-01-13 2022-09-20 사이토딘 인크. Ccr5 양성 전이성 암 치료를 위한 ccr5 결합제
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
CA2355607A1 (en) * 1998-12-16 2000-06-22 Progenics Pharmaceuticals, Inc. Anti-ccr5 antibody
JP3459386B2 (ja) 1999-10-15 2003-10-20 Ｓｍｃ株式会社 可逆式取付機構を有する流体圧機器

Also Published As

Publication number Publication date
EP1478738A1 (en) 2004-11-24
AU2003217674A1 (en) 2003-09-09
EP2058006A1 (en) 2009-05-13
DK1478738T3 (da) 2009-03-09
CA2476901A1 (en) 2003-09-04
IL163655A0 (en) 2005-12-18
CA2476901C (en) 2012-10-09
JP2006508631A (ja) 2006-03-16
CN1780907A (zh) 2006-05-31
EP1478738A4 (en) 2006-05-31
HK1072272A1 (en) 2005-08-19
WO2003072766A1 (en) 2003-09-04
EP1478738B1 (en) 2008-11-12
ES2316740T3 (es) 2009-04-16
PT1478738E (pt) 2009-02-16
NO20043971L (no) 2004-11-16
ATE414142T1 (de) 2008-11-15
CY1108799T1 (el) 2014-04-09
MXPA04008153A (es) 2005-07-05
AU2003217674C1 (en) 2009-03-26
KR20050004784A (ko) 2005-01-12
CN1780907B (zh) 2011-06-15
NZ561465A (en) 2009-04-30
AU2003217674B2 (en) 2008-10-30
DE60324664D1 (de) 2008-12-24
RU2004128252A (ru) 2005-04-10
NZ534947A (en) 2008-03-28
RU2322454C2 (ru) 2008-04-20

Similar Documents

Publication Publication Date Title
HK1072272A1 (en) Anti-ccr5 antibody
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
CY1110689T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
WO2003055527A3 (en) Immunoconjugates useful for treatment of tumours
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
IN2009KN02655A (es)
HK1019014A1 (en) Multivalent single chain antibodies
LU92710I2 (fr) Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza)
EP2267034A3 (en) Gold-binding protein and use thereof
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
PT778891E (pt) Anticorpo monoclonal recombinante anti-rhesus d (d7c2)
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
WO2005003171A3 (en) Modified antibody fragments
NZ607711A (en) Antibodies directed to her-3 and uses thereof
DK3572508T1 (da) Hybrid-antistoffer indeholdende tunge kæder med humane VDJ områder og tungkæde konstante områder fra mus og lette kæder med humane VJ områder og letkæde konstante områder fra mus.
NZ598594A (en) Combinatorial therapy involving alpha5beta1 antagonists
DE69409225D1 (de) Verbindungen für zielrichtung
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
AU2003273423A1 (en) Mutant fab fragments of the chimeric 13b8.2 anti-cd4 antibody and uses thereof
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
GR3029483T3 (en) Antibodies against t-cells as therapeutics
WO2004050849A8 (en) Recombinant immunotoxin and use in treating tumors
WO2004029214A3 (en) Lfa-1 alpha subunit antibodies and methods of use
NZ527173A (en) Specific human antibodies for selective cancer therapy